In both acute myeloid leukemia (AML) and synovial sarcoma (SS), targeting BRD9 disrupts oncogenic transcriptional programs, including MYC, leading to reduced proliferation and induction of apoptosis. Researchers from Pamplona Therapeutics (Shenzhen) Co. Ltd. reported the discovery and preclinical efficacy profile of XYD-270, a BRD9-targeting PROTAC, in models of SS and AML.
Scientists at Guangzhou Imd Therapeutics Co. Ltd. and Pamplona Therapeutics (Shenzhen) Co. Ltd. have described proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety through a linker reported to be useful for the treatment of atopic dermatitis, autoimmune disease, cancer, cardiovascular, eye and inflammatory disorders, rheumatoid arthritis and inflammatory bowel disease, among others.
